- Home
- GGAL vs LEGN Comparison
GGAL vs LEGN Comparison
Compare GGAL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGAL
- LEGN
- Stock Information
- Founded
- GGAL 1905
- LEGN 2014
- Country
- GGAL Argentina
- LEGN United States
- Employees
- GGAL N/A
- LEGN N/A
- Industry
- GGAL Commercial Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- GGAL Finance
- LEGN Health Care
- Exchange
- GGAL Nasdaq
- LEGN Nasdaq
- Market Cap
- GGAL 9.4B
- LEGN 7.0B
- IPO Year
- GGAL N/A
- LEGN 2020
- Fundamental
- Price
- GGAL $61.79
- LEGN $27.69
- Analyst Decision
- GGAL Strong Buy
- LEGN Strong Buy
- Analyst Count
- GGAL 4
- LEGN 13
- Target Price
- GGAL $59.00
- LEGN $75.67
- AVG Volume (30 Days)
- GGAL 1.1M
- LEGN 1.5M
- Earning Date
- GGAL 01-01-0001
- LEGN 05-13-2025
- Dividend Yield
- GGAL 3.84%
- LEGN N/A
- EPS Growth
- GGAL 120.03
- LEGN N/A
- EPS
- GGAL 1.06
- LEGN N/A
- Revenue
- GGAL $6,697,505,438.00
- LEGN $728,303,000.00
- Revenue This Year
- GGAL $11.73
- LEGN $65.96
- Revenue Next Year
- GGAL N/A
- LEGN $52.55
- P/E Ratio
- GGAL $6.54
- LEGN N/A
- Revenue Growth
- GGAL N/A
- LEGN 112.46
- 52 Week Low
- GGAL $23.53
- LEGN $29.27
- 52 Week High
- GGAL $74.00
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- GGAL 56.75
- LEGN 29.04
- Support Level
- GGAL $57.11
- LEGN $30.25
- Resistance Level
- GGAL $63.69
- LEGN $33.30
- Average True Range (ATR)
- GGAL 2.37
- LEGN 1.78
- MACD
- GGAL 0.16
- LEGN -0.53
- Stochastic Oscillator
- GGAL 69.70
- LEGN 3.10
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.